Maeta M, Koga S, Yamane T, Shimizu N, Oda M, Masaki T, Yoshida Y, Watnabe S, Tanida O, Kishimoto H
Gan To Kagaku Ryoho. 1984 Jan;11(1):69-74.
We have previously reported the clinical effects of NF therapy (NCS + 5-FU) and NFO therapy (NCS + 5-FU + Picibanil) on patients with advanced carcinoma of the digestive organs. In the present study, (NHO therapy (NCS + HCFU + Picibanil) performed in 41 patients and 30 patients were evaluated for its clinical effects. In comparison with NHO, NF and NFO, partial regression (tumor regression exceeding 50%) was noted in 5 of 30 patients (16.7%) on NHO, which was superior to 7.4% on NF, but slightly inferior to 18.8% on NFO. However, six and twelve month survival rate and 50% survival month on NHO therapy were 31.6%, 10.5% and 4.6 months, respectively and they were superior to those of NF and NFO therapy. Though the incidence of the adverse effects by NHO was almost identical with that of NFO and not more frequent than that of NF therapy. Urinary frequency, hot sensation and urgency due to HCFU administration were observed approximately in 10% on NFO therapy. In the three modalities the advantageous clinical effects on patients with hepatic carcinoma irrespective of primary or metastatic were observed.
我们之前已经报道了NF疗法（NCS + 5-氟尿嘧啶）和NFO疗法（NCS + 5-氟尿嘧啶 + 沙培林）对晚期消化器官癌患者的临床疗效。在本研究中，对41例接受NHO疗法（NCS + 羟基脲 + 沙培林）的患者中的30例进行了临床疗效评估。与NHO、NF和NFO相比，30例接受NHO治疗的患者中有5例（16.7%）出现部分缓解（肿瘤缩小超过50%），这一比例高于NF治疗的7.4%，但略低于NFO治疗的18.8%。然而，NHO治疗的6个月和12个月生存率以及50%生存率分别为31.6%、10.5%和4.6个月，均优于NF和NFO治疗。虽然NHO引起的不良反应发生率与NFO几乎相同，且不比NF治疗更频繁。NFO治疗中约10%的患者出现了因羟基脲给药导致的尿频、热感和尿急。在这三种治疗方式中，均观察到对原发性或转移性肝癌患者具有有利的临床效果。
